Severe Periocular Edema after Intraarterial Carboplatin Chemotherapy for Retinoblastoma in a Rabbit () Model.

Comp Med

Department of Pathology, Microbiology, and Immunology, Division of Comparative Medicine, Vanderbilt University Medical Center, Nashville, Tennessee;, Email:

Published: April 2020

Endovascular microcatheter-based intraarterial (ophthalmic artery) chemotherapy is becoming widely used for the clinical treatment of intraocular retinoblastoma due to its apparent increased efficacy compared with traditional intravenous chemotherapy; however local ocular complications are not uncommon. Carboplatin is a chemotherapeutic agent used in both intravenous and intraarterial chemotherapy. We used rabbits to assess pharmacokinetics and ocular and systemic toxicity after intraarterial carboplatin infusion. Subsequent to unilateral intraarterial administration of carboplatin, severe unilateral or bilateral periocular edema occurred in 6 adult male New Zealand white rabbits. Time to onset varied from less than 4 h after administration ( = 3, 50 mg) to approximately 24 h afterward ( = 3, 25 mg). After becoming symptomatic, 5 of the 6 animals were promptly euthanized, and the remaining animal (25 mg treatment) was medically managed for 4 d before being euthanized due to intractable edema-related lagophthalmos. Globes and orbits from all 6 euthanized rabbits were harvested en bloc; whole-mount sections were prepared for histologic evaluation, which revealed drug-induced vasogenic edema in confined spaces as the main underlying pathogenesis. Transient and self-limiting periocular edema is a common side effect of intraarterial chemotherapy but is thought to occur predominantly with melphalan monotherapy or combination therapy using melphalan, carboplatin, and topotecan. The severity of this adverse consequence in rabbits was unexpected, and its use in the study was subsequently discontinued. Although the definitive cause for this vasotoxicity and striking clinical presentation is unknown, we suspect species-specific anatomic features and sensitivity might have contributed to amplified complications after intraarterial carboplatin chemotherapy of the eye. Due to the adverse effects of intraarterial carboplatin chemotherapy that we observed in 2 experimental cohorts of rabbits, we recommend caution regarding its use in this species.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7137546PMC
http://dx.doi.org/10.30802/AALAS-CM-18-000146DOI Listing

Publication Analysis

Top Keywords

intraarterial carboplatin
16
periocular edema
12
carboplatin chemotherapy
12
intraarterial
8
intraarterial chemotherapy
8
carboplatin
7
chemotherapy
7
rabbits
5
severe periocular
4
edema
4

Similar Publications

Single- Versus Triple-Agent Intra-Arterial Chemotherapy for Retinoblastoma.

Am J Ophthalmol

January 2025

From the Department of Ophthalmology and Vision Sciences, The Hospital for Sick Children (N.O.A., K.C., A.M., B.L.G., S.N.K.), Toronto, Canada; Department of Ophthalmology and Vision Sciences, University of Toronto (N.O.A., A.M., B.L.G., S.N.K.), Toronto, Canada. Electronic address:

Article Synopsis
  • The study aimed to compare outcomes of single-agent (melphalan) versus triple-agent (melphalan, topotecan, carboplatin) intra-arterial chemotherapy for retinoblastoma (RB) in children, focusing on eye salvage.
  • Researchers reviewed cases of 37 children under 18 who underwent intra-arterial chemotherapy from 2016 to 2024, analyzing complications, tumor responses, and survival rates.
  • Results showed that the triple-agent therapy had a higher rate of partial or complete tumor response (91% vs. 62%), but ocular complications were similar between both groups (31% single-agent vs. 52% triple-agent).
View Article and Find Full Text PDF

Purpose: To determine whether the administration of intra-arterial carboplatin affected the hearing of children with retinoblastoma.

Methods: Children with retinoblastoma who were treated with intra-arterial carboplatin chemotherapy were included. Hearing tests before chemotherapy including tympanometry, distortion product otoacoustic emissions, and audiogram (if achievable) were performed and repeated 3 to 9 months after concluding intra-arterial therapy.

View Article and Find Full Text PDF

Intraarterial chemotherapy (Ophthalmic Artery Chemosurgery/OAC) for retinoblastoma has transformed management of retinoblastoma worldwide since Pierre Gobin MD and I introduced it in 2006. Case reports, institutional series, meta-analyses, and randomized trials have validated its effectiveness and safety. It allows more eyes to be saved (at Memorial Sloan Kettering Cancer Center (MSKCC) as a result, we have gone from removing 96% of retinoblastoma eyes that presented with leukocoria (comparable to modern day International Classification "D" and "E" eyes) to saving 95% of these eyes with primary OAC management allows the majority of advanced intraocular eyes to be salvaged (both "D" and "E" eyes) prior to the chemoreduction era to saving 95% of these eyes with primary OAC management.

View Article and Find Full Text PDF

Background: Utilizing an endovascular rat glioma model, this study aimed to analyze the efficacy of intra-arterial (IA) carboplatin and bevacizumab delivery with blood-brain barrier breakdown (BBBB) for glioblastoma treatment.

Methods: C6-glioma cells were stereotactically injected into the left frontal lobe of Wistar rats. Tumor growth was confirmed on day 8 via MRI.

View Article and Find Full Text PDF

Pancreatic adenocarcinoma refers to cancer of the pancreatic duct cells. It is normally diagnosed when it is at an advanced stage, making the prognosis poor. Systemic chemotherapy is the primary treatment approach for locally advanced or metastatic pancreatic cancer and has been shown to improve survival by eight to 16 weeks.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!